- Home
- ENSC vs RNAZ Comparison
ENSC vs RNAZ Comparison
Compare ENSC & RNAZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENSC
- RNAZ
- Stock Information
- Founded
- ENSC 2003
- RNAZ 2016
- Country
- ENSC United States
- RNAZ United States
- Employees
- ENSC N/A
- RNAZ N/A
- Industry
- ENSC Biotechnology: Pharmaceutical Preparations
- RNAZ Biotechnology: Pharmaceutical Preparations
- Sector
- ENSC Health Care
- RNAZ Health Care
- Exchange
- ENSC Nasdaq
- RNAZ Nasdaq
- Market Cap
- ENSC 5.5M
- RNAZ 6.1M
- IPO Year
- ENSC N/A
- RNAZ 2021
- Fundamental
- Price
- ENSC $2.13
- RNAZ $9.94
- Analyst Decision
- ENSC
- RNAZ Strong Buy
- Analyst Count
- ENSC 0
- RNAZ 1
- Target Price
- ENSC N/A
- RNAZ $280.00
- AVG Volume (30 Days)
- ENSC 84.7K
- RNAZ 26.6K
- Earning Date
- ENSC 08-13-2025
- RNAZ 08-13-2025
- Dividend Yield
- ENSC N/A
- RNAZ N/A
- EPS Growth
- ENSC N/A
- RNAZ N/A
- EPS
- ENSC N/A
- RNAZ N/A
- Revenue
- ENSC $6,224,081.00
- RNAZ N/A
- Revenue This Year
- ENSC N/A
- RNAZ N/A
- Revenue Next Year
- ENSC $1,381.48
- RNAZ N/A
- P/E Ratio
- ENSC N/A
- RNAZ N/A
- Revenue Growth
- ENSC 256.35
- RNAZ N/A
- 52 Week Low
- ENSC $1.62
- RNAZ $6.15
- 52 Week High
- ENSC $14.67
- RNAZ $877.71
- Technical
- Relative Strength Index (RSI)
- ENSC 45.62
- RNAZ 60.71
- Support Level
- ENSC $1.97
- RNAZ $8.28
- Resistance Level
- ENSC $2.40
- RNAZ $9.15
- Average True Range (ATR)
- ENSC 0.17
- RNAZ 0.71
- MACD
- ENSC -0.00
- RNAZ 0.26
- Stochastic Oscillator
- ENSC 37.21
- RNAZ 85.34
About ENSC Ensysce Biosciences Inc.
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.
About RNAZ TransCode Therapeutics Inc.
TransCode Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing innovative drugs and diagnostics for treating and identifying cancer. TransCode recently commenced its first clinical trial. The Company's lead therapeutic candidate, TTX-MC138, comprises an oligonucleotide conjugated to an iron oxide nanoparticle designed to be administered by infusion to inhibit the ability of metastatic tumor cells to survive. The goal of the therapy, if approved, is to achieve durable disease regression and long-term patient survival.